Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21364654 | 1.00 | CYP2D6 (0.49) | CYP2D6KCNH2HDAC1TSHR | |
| SCHEMBL3437194 | 0.78 | CYP2D6 (0.46) | CYP2D6KCNH2 | |
| SCHEMBL3436926 | 0.77 | CYP2D6 (0.65) | CYP2D6KCNH2 | |
| SCHEMBL3437198 | 0.77 | CYP2D6 (0.65) | CYP2D6KCNH2 | |
| SCHEMBL3437071 | 0.76 | CYP2D6 (0.64) | CYP2D6KCNH2 | |
| SCHEMBL3437076 | 0.75 | CYP2D6 (0.47) | CYP2D6KCNH2 | |
| SCHEMBL3436883 | 0.75 | CYP2D6 (0.47) | CYP2D6KCNH2 | |
| SCHEMBL3437200 | 0.75 | CYP2D6 (0.47) | CYP2D6KCNH2 | |
| SCHEMBL21364546 | 0.73 | CYP2D6 (0.70) | CYP2D6KCNH2 | |
| SCHEMBL3436928 | 0.72 | CYP2D6 (0.56) | CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242174-B2 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120157462-A1 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC | 2012-06-21 | — | — | US | disclosed |
| US-7807720-B2 | Hydroxamic acid derivatives of 3-phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807720-B2 | Hydroxamic acid derivatives of 3-phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807720-B2 | Hydroxamic acid derivatives of 3-phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC (US) | 2010-10-05 | — | — | US | disclosed |
| WO-2008147480-A2 | HYDROXAMIC ACID DERIVATIVES OF 3-PHENYL PROPIONIC ACIDS USEFUL AS THRAPEUTIC AGENTS FOR TREATING ANTHRAX POISONING | PANTHERA BIOPHARNA, LLC. (US) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008147480-A2 | HYDROXAMIC ACID DERIVATIVES OF 3-PHENYL PROPIONIC ACIDS USEFUL AS THRAPEUTIC AGENTS FOR TREATING ANTHRAX POISONING | PANTHERA BIOPHARNA, LLC. (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080188566-A1 | Hydroxamic acid derivatives of 3-Phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning | PAN THERA BIOPHARMA,LLC | 2008-08-07 | — | — | US | disclosed |
| US-20080188566-A1 | Hydroxamic acid derivatives of 3-Phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning | PAN THERA BIOPHARMA,LLC | 2008-08-07 | — | — | US | disclosed |
| US-20080188566-A1 | Hydroxamic acid derivatives of 3-Phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning | PAN THERA BIOPHARMA,LLC | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157462-A1 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | ANTXR2, AGXT, AADAC | CYP2D6 941/4885KCNH2 3164/4885HDAC1 60/4885 |
| US-20080188566-A1 | Hydroxamic acid derivatives of 3-Phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning | ANTXR2, PAOX, AGXT | CYP2D6 1351/4885KCNH2 3321/4885HDAC1 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.